Back to top
more

Akebia Therapeutics (AKBA)

(Delayed Data from NSDQ)

$1.21 USD

1.21
2,315,723

-0.12 (-9.02%)

Updated May 10, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AKBA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Akebia Therapeutics, Inc. [AKBA]

Reports for Purchase

Showing records 41 - 60 ( 81 total )

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 41

09/03/2020

Industry Report

Pages: 4

Biotechnology - A Return to Biotech Inflows

Provider: Piper Sandler

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 42

08/27/2020

Daily Note

Pages: 3

Vadadustat Launched in Japan; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 43

08/12/2020

Company Report

Pages: 7

New Guard Takes Charge of the Strengthened Company; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 44

07/15/2020

Daily Note

Pages: 4

Vadadustat Could Reduce Lung Injury in COVID-19 Patients With ARDS; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 45

06/30/2020

Daily Note

Pages: 3

VAFSEO (vadadustat) Approved in Japan; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 46

06/19/2020

Daily Note

Pages: 4

New CFO Complements Akebia''s Transition to a Commercial Launch Phase Company

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 47

05/06/2020

Company Report

Pages: 10

Impressive Phase 3 Data Elevates Vadadustat''s Potential; Raise PT to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 48

04/09/2020

Daily Note

Pages: 3

Fortifies Vadadustat Supply Chain With Third Supply Agreement; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 49

03/30/2020

Daily Note

Pages: 94

Market Shudders But We See Names to Outperform.

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 50

03/11/2020

Company Report

Pages: 6

Akebia Enters a Defining Year Poised for Success; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 51

02/19/2020

Company Report

Pages: 8

PRV Purchase for Vadadustat to Meaningfully Improve Its Competitive Position; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 52

11/18/2019

Company Report

Pages: 8

3Q19 Recap: Value Creation Approaches With Vadadustat Readouts by Mid-2020; Moderate PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 53

10/16/2019

Daily Note

Pages: 4

Enough Is Enough- Akebia Sues CMS Over Decision on Auryxia; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 54

09/05/2019

Daily Note

Pages: 3

The Countdown Begins: Global Phase 3 Vadadustat Program Fully Enrolled; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 55

08/09/2019

Company Report

Pages: 8

2Q19 Recap: Vadadustat''s Full Pivotal Data Set a Year Away; Auryxia Growth Finds Its Footing; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 56

08/06/2019

Company Report

Pages: 9

Auryxia Patent Settlement With Par Reduces Our Estimated LOE; PT to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 57

07/24/2019

Company Report

Pages: 7

Vadadustat NDA Submitted in Japan; Model Refresh; Moderating PT to $19

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 58

07/11/2019

Company Report

Pages: 8

Study Supports Outcomes Benefit on Auryxia; Moderating Sales Trajectory; PT to $21

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 59

05/10/2019

Company Report

Pages: 8

1Q19 Recap; Competitor Stumble on MACE Highlights Clean Trial Design and Safety Profile of Vadadustat; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 60

04/03/2019

Company Report

Pages: 7

Putative Case of Hy''s Law Misunderstood; Adding Auryxia to Model; Raise PT to $23

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party